tradingkey.logo

Abivax surges on report of renewed Lilly buyout speculation

ReutersJan 12, 2026 11:22 AM

U.S.-listed shares of French biotech firm Abivax ABVX.PA, ABVX.O rise 32% to $151 premarket after fresh takeover chatter

U.S. pharma giant Eli Lilly LLY.N may bid 15 billion euros ($17.52 billion) for Abivax, nearly double its current market cap, French media reports

Abivax and Eli Lilly did not immediately respond to Reuters requests for comment

Abivax is developing an experimental drug, obefazimod, for the treatment of ulcerative colitis and its CEO has said it could become a widely used product

The first takeover rumors linking Eli Lilly to Abivax surfaced on December 10

ABVX soared 1,749% in 2025

($1 = 0.8560 euros)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI